Bronchiectasis

Bronchiectasis is a chronic, irreversible structural dilation of the bronchi and bronchioles, characterized by destruction of the elastic and muscular components of the bronchial walls, leading to permanent airway enlargement. This condition results from a vicious cycle of inflammation, infection, and impaired mucociliary clearance, ultimately causing progressive airway damage and loss of pulmonary function. In veterinary medicine, bronchiectasis is most commonly recognized in dogs and cats, often as a sequela of chronic respiratory disease, aspiration pneumonia, or severe infectious tracheobronchitis. The disease is classified into three main morphological types: cylindrical (fusiform), saccular, and varicose bronchiectasis, based on the pattern of airway dilation. Cylindrical bronchiectasis involves uniform dilation of the bronchi, saccular bronchiectasis presents as balloon-like outpouchings, and varicose bronchiectasis shows irregular, beaded dilation. The condition is typically progressive and irreversible, with significant impact on gas exchange and respiratory function. Early diagnosis and management are crucial to slow disease progression and improve quality of life.

The etiology of bronchiectasis in veterinary patients is multifactorial, with several primary causes identified. Chronic infectious diseases, particularly bacterial pneumonia (e.g., Bordetella bronchiseptica, Streptococcus spp., Escherichia coli, Pseudomonas aeruginosa) and mycoplasma infections, are common triggers. Viral infections such as canine distemper virus and canine influenza virus can also predispose to bronchiectasis by causing severe bronchial damage. Fungal infections (e.g., Aspergillus spp., Histoplasma capsulatum) and parasitic infestations (e.g., Filaroides osleri, Oslerus osleri) are less common but significant causes. Aspiration pneumonia, often due to esophageal disorders (e.g., megaesophagus, hiatal hernia) or laryngeal paralysis, is a major risk factor. Chronic bronchitis, especially in dogs, can lead to bronchiectasis over time. Additionally, primary ciliary dyskinesia, a genetic disorder affecting mucociliary clearance, is a well-documented cause in young dogs, particularly in breeds like the Old English Sheepdog and Bichon Frise. Other contributing factors include foreign body inhalation, bronchial obstruction (e.g., tumors, foreign bodies), and immune-mediated diseases. In some cases, the exact cause remains idiopathic. The underlying mechanism involves persistent inflammation and infection that damage the bronchial wall, leading to loss of structural integrity and permanent dilation.

Bronchiectasis is relatively uncommon in veterinary medicine but is increasingly recognized with advanced imaging. It is more frequently diagnosed in dogs than cats. In dogs, certain breeds are predisposed, including West Highland White Terriers, Cocker Spaniels, Poodles, and Old English Sheepdogs, the latter often associated with primary ciliary dyskinesia. Middle-aged to older animals are more commonly affected, reflecting the chronic nature of the disease. No clear sex predilection has been reported. In cats, bronchiectasis is often associated with chronic bronchitis or asthma, and breeds such as Siamese may be overrepresented. Geographic variations may exist due to endemic infectious agents (e.g., fungal diseases in certain regions). The true incidence is unknown, but it is likely underdiagnosed due to the need for advanced imaging (CT) for definitive diagnosis. The condition is more prevalent in animals with a history of recurrent respiratory infections or chronic airway disease.

The pathophysiology of bronchiectasis involves a complex interplay of inflammation, infection, and impaired mucociliary clearance. The initial insult, whether infectious, obstructive, or immune-mediated, leads to bronchial wall inflammation. Neutrophils and macrophages infiltrate the airway, releasing proteases (e.g., elastase) and reactive oxygen species that damage the bronchial epithelium and underlying structural components, including elastic fibers, smooth muscle, and cartilage. This damage results in loss of bronchial wall integrity and permanent dilation. Concurrently, mucociliary clearance is impaired due to ciliary dysfunction (as in primary ciliary dyskinesia) or excessive mucus production, leading to mucus stasis and bacterial colonization. Chronic bacterial infection perpetuates the inflammatory response, creating a self-sustaining cycle of tissue destruction and further dilation. The dilated airways become reservoirs for bacteria, leading to recurrent pneumonia and systemic inflammation. Over time, the disease progresses, causing airway obstruction, ventilation-perfusion mismatch, and hypoxemia. Secondary pulmonary hypertension may develop due to chronic hypoxia and vascular remodeling. The irreversible nature of the structural changes underscores the importance of early intervention to halt progression.

Several factors predispose animals to bronchiectasis. Intrinsic factors include genetic disorders such as primary ciliary dyskinesia, which impairs mucociliary clearance from birth, and congenital bronchial cartilage hypoplasia. Age is a risk factor, as chronic respiratory diseases accumulate over time. Immunosuppression, whether due to concurrent disease (e.g., hyperadrenocorticism, diabetes mellitus) or iatrogenic (e.g., corticosteroid therapy), increases susceptibility to infections. Extrinsic factors include environmental pollutants, smoke exposure, and poor ventilation, which can exacerbate airway inflammation. Dietary factors, such as obesity, can impair respiratory mechanics. Concurrent conditions like megaesophagus or laryngeal paralysis predispose to aspiration pneumonia, a major trigger. Chronic bronchitis, especially in dogs, is a significant risk factor. In cats, chronic asthma and bronchitis are common precursors. Additionally, recurrent respiratory infections, particularly in young animals, may lead to bronchiectasis later in life. Management of these predisposing factors is essential to prevent disease onset or progression.

Clinical signs of bronchiectasis are often chronic and progressive. The most common sign is a chronic, productive cough, which may be worse in the morning or after exercise. The cough is often described as 'moist' or 'productive,' with production of purulent or mucoid sputum. In some cases, hemoptysis may occur due to bronchial artery erosion. Affected animals may exhibit exercise intolerance, tachypnea, and respiratory distress, especially during exacerbations. Systemic signs include lethargy, anorexia, and weight loss. On physical examination, crackles and wheezes may be auscultated over the affected lung fields, and in severe cases, cyanosis may be present. In dogs with concurrent megaesophagus, regurgitation may be observed. Cats may present with a chronic cough and intermittent respiratory distress. The clinical course is often punctuated by acute exacerbations, characterized by worsening cough, fever, and increased respiratory effort, often due to secondary bacterial pneumonia. In advanced stages, signs of right-sided heart failure (e.g., ascites, jugular distension) may develop due to cor pulmonale.

Differential diagnoses for bronchiectasis include chronic bronchitis, which is characterized by reversible airway inflammation and no structural dilation; bronchopneumonia, which presents with acute or chronic infection and may show alveolar infiltrates on imaging; pulmonary fibrosis, which involves interstitial lung disease with restrictive pattern; asthma (feline), which is reversible bronchoconstriction with eosinophilic inflammation; neoplasia (e.g., primary lung tumors, lymphoma), which may cause mass lesions or airway obstruction; foreign body aspiration, which can cause localized bronchiectasis; and parasitic infections (e.g., lungworms) that may cause chronic airway disease. To differentiate, imaging is key: bronchiectasis shows bronchial dilation with lack of tapering, visible on radiographs or CT. Bronchoscopy can directly visualize dilated airways and collect samples for cytology and culture. Chronic bronchitis typically shows normal bronchial diameter but increased mucus. Bronchopneumonia shows alveolar infiltrates and responds to antibiotics. Pulmonary fibrosis shows interstitial patterns and restrictive physiology. Asthma in cats is characterized by eosinophilic inflammation and reversible airway obstruction. Neoplasia may show mass lesions on imaging. Foreign body aspiration may be identified via bronchoscopy. Lungworm infections can be diagnosed via fecal examination or PCR.

The diagnostic approach to bronchiectasis begins with a thorough history and physical examination, focusing on respiratory signs and potential underlying causes. Thoracic radiographs are the initial imaging modality; findings may include bronchial wall thickening, dilated bronchi that appear as 'tram lines' or 'ring shadows,' and lack of tapering of bronchi toward the periphery. However, radiographs may be normal in early disease. If bronchiectasis is suspected, computed tomography (CT) is the gold standard for diagnosis, providing detailed cross-sectional images that confirm bronchial dilation and characterize the extent and type. Bronchoscopy is recommended to directly visualize the airways, assess for foreign bodies or masses, and collect bronchoalveolar lavage (BAL) fluid for cytology, culture, and sensitivity testing. Additional tests include complete blood count, serum biochemistry, and urinalysis to identify underlying systemic diseases. Fecal examination (e.g., Baermann technique) may be performed to rule out lungworms. In cases of suspected primary ciliary dyskinesia, nasal or bronchial mucosal biopsy for electron microscopy can assess ciliary ultrastructure. Genetic testing may be available for certain breeds. The diagnostic algorithm should be systematic, starting with non-invasive imaging and progressing to more invasive procedures as needed.

Laboratory findings in bronchiectasis are often non-specific but may reflect chronic inflammation or underlying disease. Hematology may show a mild to moderate leukocytosis with neutrophilia, particularly during acute exacerbations. Eosinophilia may be present in cases of parasitic or allergic disease. Serum biochemistry may reveal elevated globulins due to chronic antigenic stimulation, and liver enzyme elevations may occur if there is concurrent hepatic disease. In cases of cor pulmonale, there may be evidence of polycythemia due to chronic hypoxia. Arterial blood gas analysis may show hypoxemia and, in advanced cases, hypercapnia. Bronchoalveolar lavage (BAL) fluid analysis is crucial: cytology typically shows neutrophilic inflammation, with or without bacteria; culture and sensitivity testing identify the causative organisms. In cats with asthma, eosinophils may predominate. Specific biomarkers such as C-reactive protein (CRP) may be elevated during exacerbations. Serology or PCR for infectious agents (e.g., Mycoplasma, Bordetella, Aspergillus) may be helpful. In cases of primary ciliary dyskinesia, electron microscopy of cilia shows ultrastructural defects. Genetic testing for specific mutations (e.g., CCDC39 in Old English Sheepdogs) is available.

Imaging plays a pivotal role in the diagnosis of bronchiectasis. Thoracic radiographs may show bronchial wall thickening, increased bronchial opacity, and dilated bronchi that appear as 'tram lines' (parallel lines) or 'ring shadows' (end-on bronchi). The bronchi may fail to taper toward the periphery, and in severe cases, saccular or cystic changes may be visible. However, radiographs have limited sensitivity, especially for mild or early disease. Computed tomography (CT) is the gold standard, providing high-resolution cross-sectional images that clearly demonstrate bronchial dilation, lack of tapering, and bronchial wall thickening. CT also allows assessment of the extent and distribution of disease, which is important for prognosis and treatment planning. Bronchoscopy is an essential adjunct, allowing direct visualization of the airways, identification of mucus plugs or foreign bodies, and collection of BAL fluid. In some cases, fluoroscopy may be used to assess dynamic airway collapse. Ultrasonography is not typically used for bronchiectasis but may be helpful to evaluate for concurrent conditions such as megaesophagus. Echocardiography may be indicated if pulmonary hypertension is suspected.

Cytological and histopathological findings in bronchiectasis reflect chronic inflammation and structural damage. Bronchoalveolar lavage (BAL) fluid cytology typically shows a marked neutrophilic inflammation, with degenerate neutrophils and possibly intracellular bacteria. Macrophages may be present, and in chronic cases, foamy macrophages containing lipid or hemosiderin may be seen. Eosinophils may be prominent in cases of parasitic or allergic disease. Culture of BAL fluid is essential to identify bacterial pathogens and guide antimicrobial therapy. Histopathological examination of bronchial biopsies (obtained via bronchoscopy or at necropsy) reveals destruction of the bronchial wall, including loss of elastic fibers, smooth muscle, and cartilage. The epithelium may show squamous metaplasia or ulceration. There is often a dense inflammatory infiltrate, predominantly neutrophils and lymphocytes, with fibrosis of the bronchial wall. In advanced cases, there may be peribronchial fibrosis and alveolar destruction. Special stains (e.g., Gram stain, Gomori methenamine silver) may be used to identify organisms. Histopathology is rarely performed antemortem due to the invasive nature, but it is valuable for confirming the diagnosis and ruling out other causes.

Treatment of bronchiectasis is multifaceted and aims to control infection, reduce inflammation, improve mucociliary clearance, and manage underlying causes. Antimicrobial therapy is the cornerstone, based on culture and sensitivity results from BAL fluid. Common antibiotics include amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h), doxycycline (5-10 mg/kg PO q12h), and fluoroquinolones such as enrofloxacin (5-10 mg/kg PO q24h) or marbofloxacin (2.75-5.5 mg/kg PO q24h). In cases of Pseudomonas infection, combination therapy with an aminoglycoside (e.g., amikacin 15-20 mg/kg IV/SC q24h) may be necessary. Anti-inflammatory therapy with corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q24h, tapering) may be used to reduce airway inflammation, but caution is needed to avoid immunosuppression. Bronchodilators such as theophylline (10-20 mg/kg PO q12h in dogs; 15-20 mg/kg PO q24h in cats) or terbutaline (0.01 mg/kg SC or 0.625-1.25 mg/dog PO q8-12h) may help improve airflow. Mucolytics like N-acetylcysteine (50-100 mg/kg PO q12h) or nebulized saline may aid in mucus clearance. Chest physiotherapy, including coupage and exercise, can help mobilize secretions. In severe cases, surgical resection of affected lung lobes may be considered, but it is rarely performed. Management of underlying conditions (e.g., megaesophagus, laryngeal paralysis) is essential. Supportive care includes oxygen therapy during exacerbations, nutritional support, and weight management.

The prognosis for bronchiectasis is generally guarded to poor, as the structural changes are irreversible. However, with appropriate management, many animals can have a good quality of life for months to years. Prognostic factors include the extent of disease, underlying cause, and response to therapy. Animals with localized disease and a treatable underlying cause (e.g., foreign body) may have a better prognosis. Conversely, diffuse disease, chronic Pseudomonas infection, and concurrent cor pulmonale are associated with a poorer prognosis. Acute exacerbations can be life-threatening, especially if severe pneumonia or respiratory failure develops. The median survival time in dogs with bronchiectasis is reported to be around 1-2 years, but this varies widely. Regular monitoring and aggressive management of exacerbations can improve outcomes. Owners should be counseled about the chronic nature of the disease and the need for long-term therapy.

Follow-up care for bronchiectasis is essential to monitor disease progression and adjust therapy. Re-evaluation should occur every 1-3 months initially, then every 3-6 months if stable. At each visit, a thorough physical examination, including thoracic auscultation, should be performed. Thoracic radiographs may be repeated every 6-12 months to assess progression, but CT is more sensitive and may be repeated if clinical signs worsen. Serial BAL fluid analysis and culture may be indicated if there is poor response to therapy or recurrent exacerbations. Blood work, including CBC and serum biochemistry, should be monitored periodically to assess for systemic effects and drug toxicity. Owners should be educated to recognize early signs of exacerbation (e.g., increased coughing, lethargy, fever) and seek prompt veterinary care. Long-term management includes continued antimicrobial therapy (possibly pulse dosing), anti-inflammatory drugs, and mucolytics. Adjustments to drug dosages may be needed based on renal or hepatic function. In cases of cor pulmonale, cardiac monitoring (e.g., echocardiography) is recommended.

Pearls: 1) Always consider bronchiectasis in any animal with a chronic, productive cough that does not respond to standard therapy. 2) CT is the gold standard for diagnosis; radiographs can be falsely negative. 3) Bronchoscopy with BAL is essential for identifying the causative organism and guiding antimicrobial therapy. 4) In young dogs with recurrent respiratory infections, consider primary ciliary dyskinesia. 5) Aggressive management of underlying conditions (e.g., megaesophagus) can prevent progression. Pitfalls: 1) Do not rely solely on radiographs; they may miss early or mild disease. 2) Avoid indiscriminate use of corticosteroids without addressing infection, as this can worsen the condition. 3) Do not discontinue antibiotics prematurely; prolonged therapy is often needed. 4) Failure to perform culture and sensitivity can lead to inappropriate antibiotic selection and antimicrobial resistance. 5) Overlooking concurrent conditions such as pulmonary hypertension can lead to inadequate treatment.

Antimicrobial therapy: Amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) is a first-line choice for community-acquired infections. Doxycycline (5-10 mg/kg PO q12h) is effective against Mycoplasma and Bordetella. Fluoroquinolones (enrofloxacin 5-10 mg/kg PO q24h; marbofloxacin 2.75-5.5 mg/kg PO q24h) are useful for Gram-negative infections, including Pseudomonas. For Pseudomonas, combination therapy with an aminoglycoside (amikacin 15-20 mg/kg IV/SC q24h) may be needed, but monitor renal function. Anti-inflammatory therapy: Prednisone (0.5-1 mg/kg PO q24h, tapering to lowest effective dose) can reduce inflammation, but use with caution in infectious cases. Bronchodilators: Theophylline (10-20 mg/kg PO q12h in dogs; 15-20 mg/kg PO q24h in cats) or terbutaline (0.01 mg/kg SC or 0.625-1.25 mg/dog PO q8-12h) may improve airflow. Mucolytics: N-acetylcysteine (50-100 mg/kg PO q12h) or nebulized saline (0.9% NaCl) can help thin secretions. In severe cases, inhaled antibiotics (e.g., gentamicin 50 mg/mL, 1-2 mL nebulized q12h) may be considered. Always adjust dosages for renal or hepatic impairment and monitor for drug interactions.

Evidence-based literature on bronchiectasis in veterinary medicine is limited, but several studies provide insights. A retrospective study by Johnson et al. (2008) described clinical findings and outcomes in dogs with bronchiectasis, reporting that chronic cough and recurrent pneumonia were common, and CT was superior to radiography for diagnosis. Another study by Norris et al. (2002) evaluated the use of bronchoscopy and BAL in diagnosing lower respiratory tract disease, highlighting the importance of culture and sensitivity. In terms of treatment, a consensus statement from the International Society for Companion Animal Infectious Diseases (ISCAID) on antimicrobial therapy for canine and feline respiratory infections (Lappin et al., 2017) provides guidelines for antibiotic selection and duration. A study by Vientós-Plotts et al. (2019) investigated the role of primary ciliary dyskinesia in young dogs with recurrent respiratory disease, emphasizing genetic testing. Additionally, a review by Rozanski (2014) summarized the management of chronic bronchitis and bronchiectasis, recommending a multimodal approach. While large-scale clinical trials are lacking, these studies support the use of CT, bronchoscopy, and targeted antimicrobial therapy in managing bronchiectasis.